Business Wire

KCx Integrates Proprietary Data into FlexTrade’s AI Assistant, FlxAI

12.5.2025 10:04:00 CEST | Business Wire | Press Release

Share

FlexTrade Systems, a global leader in multi-asset execution and order management systems, and Kepler Cheuvreux, a leading independent European financial services company through its KCx execution services, today announced the availability of KCx’s sophisticated analytical suite directly from FlexTrade’s AI assistant, FlxAI, to deliver intelligent, high-value insights into client workflows.

With rapid advancements in AI, large language models are reshaping how financial firms interact with data. Trading desks are increasingly embracing conversational AI to streamline decision-making and extract actionable insights faster than ever before. In response to market drivers, the new workflow has been developed as part of a collaborative initiative between KCx’s and FlexTrade’s teams.

Through the new collaboration, users of FlxAI, which is seamlessly embedded in FlexTrade's FlexONE OEMS and FlexTRADER EMS solutions, can actively query KCx liquidity drivers through natural language commands, such as "What's the anticipated closing volume according to KCx?" or "What does KCx think the volatility will be today?" FlxAI translates these requests into API commands, which are passed to KCx. KCx then returns the result, derived from vast streams of structured data — timestamps, prices, venues, order types — which FlxAI translates and presents to the end user within the order blotter as rich, human-readable narratives. These narratives explain factors such as slippage drivers, venue performance, and hidden cost patterns. Additionally, using AI, KCx’s analytics continuously learns from evolving market conditions, transforming the analytics feedback in real-time.

Further development from KCx will see their own AI chat agent launch, delivering additional proprietary data points and working order content to users directly. Through agent-to-agent communication, FlxAI will extend to this AI agent to provide answers to user questions determined to be directed to KCx.

Chris McConville, Global Head of Execution Services and Trading at KCx said: “Built on the foundation of our robust API Analytical Suite offering, this workflow integration represents a major step forward. KCx is introducing this new capability through FlexTrade, which aligns with our mission to provide accessible, high-value insights directly into our clients' workflows. Rather than only focusing on AI-driven execution algorithms, our priority is to enhance workflow efficiency — improving decision support, reducing manual processes, and simplifying interactions with complex data. This enables traders and portfolio managers to focus on more strategic, high-value tasks.”

Andy Mahoney, Managing Director, EMEA at FlexTrade, stated: “Our existing integration with KCx’s analytic suite has proved popular with clients looking to source high-quality, adaptive market intelligence. Integrating the KCx data source into FlxAI was a natural step to extend the coverage to third-party data, which is relevant, useful, and timely to users. As the sell-side finds new and unique ways to deliver content to clients, we aim to provide a seamless interface to access all services available. With FlxAI, connected to an abundance of data sources and other AI agents, this will ensure interaction is completely natural.”

Anvar Karimson, Chief Technology Officer, Kepler Cheuvreux, noted:“This innovative integration marks a significant technological advancement in delivering intelligence when traders need it most. By connecting KCx analytics with FlxAI, we're transforming how insights flow through decision workflows. Natural language interaction elegantly removes barriers between complex analysis and trading decisions. This reflects our core belief that sophisticated technology should feel intuitive while enhancing how clients interact with markets.”

KCx and FlexTrade will demonstrate this innovation at TradeTech Europe, May 13 - 15. The FlexTrade team will be in Track C during the roundtable sessions at the Buy-Side Innovation Day on May 13. Additionally, the innovation will be showcased at Booth 36 with the FlexTrade team or Booth 58 with the KCx team during the Main Conference on May 14 and 15.

About Kepler Cheuvreux:

Kepler Cheuvreux is a leading independent European financial services company that specialises in Research, Execution (KCx), Fixed Income and Credit, Structured Solutions, Corporate Finance, and Asset Management.

The group employs around 600 people and is present in 14 major financial centres in Europe, the US, and the Middle East: Amsterdam, Brussels, Dubai, Frankfurt, Geneva, London, Madrid, Milan, New York, Oslo, Paris, Stockholm, Vienna, and Zurich.

About FlexTrade:

FlexTrade Systems provides customized multi-asset execution and order management trading solutions for buy- and sell-side financial institutions. Through deep client partnerships with some of the world's largest, most complex, and demanding capital markets firms, we develop the flexible tools, technology, and innovation that give our clients a competitive edge. Our globally distributed engineering teams focus on adaptable technology and open architecture to develop highly sophisticated trading solutions that can automate and scale with your business strategies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250512589499/en/

Contacts

Iain Smith
Iain.Smith@FlexTrade.com
O: +44 20 3757 9311

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye